·PIB·15 marks·250–350 words

"India's disease burden demands a shift from curative to preventive and precision healthcare." Discuss the role of genomics and biomarkers in this transition.

New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →
In this answer
  1. Why the shift is needed
  2. Role of genomics
  3. Role of biomarkers
  4. Gaps to bridge

Precision medicine shapes care around a person's genetic profile, lifestyle and environment [1]. Diabetes, obesity, hypertension and heart disease now affect younger Indians in both cities and villages [1]. A model that only treats disease therefore acts late and costs a lot. Genomics and biomarkers let the health system predict risk and prevent disease.

Why the shift is needed

  • NCD transition: metabolic disorders are rising because diets are changing and people are less physically active [1].
  • Cost burden: chronic and rare diseases need treatment for life. The National Policy for Rare Diseases, 2021 aims to lower these high costs [4].

Role of genomics

  • Indian reference data: DBT's GenomeIndia has sequenced the whole genomes of 10,074 individuals, which it calls a foundation for precision medicine [2]. Because Indians are so genetically diverse, risk estimates built on foreign populations may not fit them [1].
  • Genetic disease diagnosis: rare disorders have no lifestyle cause, so genomics is the main tool. ICMR is widening its coverage of rare diseases [1].
  • From managing to correcting disease: the CMC Vellore haemophilia gene therapy, published in the NEJM, shows India can build its own molecular therapies [1].

Role of biomarkers

  • Risk stratification: biomarkers flag high-risk people before disease begins. For example, women who had gestational diabetes can be marked as likely to develop Type 2 diabetes later [1].
  • Targeted screening: limited screening capacity goes to the people most at risk, which makes prevention cheaper.
  • Personalised therapy: the same disease may need different treatment in different people [1].

Gaps to bridge

  • Age mismatch: NP-NCD screens only people aged 30 and above [3], so young people at high risk are left out.
  • Last-mile linkage: there are 770 District NCD Clinics and 6,410 NCD clinics at Community Health Centres [3]. Research findings still rarely reach them.
  • Ethics and equity: genomic databases raise questions of consent and privacy under the DPDP Act, 2023. Gene therapies are also costly and reach few patients.

Genomics shows who is at risk, and biomarkers show when to act. Together they turn general prevention into targeted prevention. The next steps are to:

  • feed genomic risk data and biomarker alerts into NP-NCD,
  • screen high-risk groups before age 30, and
  • use the NPRD National Consortium [4] to scale up Indian-made therapies.

This would build a prevention-first system in line with SDG 3 and Viksit Bharat 2047.

Sources

  1. 1PIB, "India's Healthcare Research Focus Shifting to Prevention Through Futuristic Strategies at Molecular and Genetic Levels: Dr Jitendra Singh" (THE WEEK Health Summit 2026): rising disease among young people, precision medicine, genetic diversity, gestational-diabetes biomarkers, ICMR rare-disease work, CMC Vellore gene therapy
  2. 2DBT, GenomeIndia Digest (27-02-2024): whole-genome sequencing of 10,074 individuals
  3. 3MoHFW/PIB, "Steps taken to Control Hypertension and Diabetes": NP-NCD screening of people aged 30 and above, NCD clinic numbers
  4. 4MoHFW/PIB, "Union Health Minister approves National Policy for Rare Diseases, 2021": aim of lowering treatment cost, National Consortium for R&D

More from this note